Literature DB >> 1716761

Screening for fetal Down's syndrome with maternal serum markers--an experience in Italy.

G Mancini1, M Perona, D Dall'Amico, C Bollati, F Albano, R Mazzone, M Rosso, A O Carbonara.   

Abstract

The effectiveness of maternal serum alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin in screening for Down's syndrome (DS) was evaluated on 840 women who underwent amniocentesis for fetal karyotype on account of their age. The risk of a DS pregnancy was established using the method of Wald et al. (1988b), which combines the age-specific risk with that indicated by the levels of the three serum markers. In women over 35, at cut-off risk levels of 1:250 and 1:380, the false-positive rate was 24 and 34 per cent, respectively. In all nine cases of DS, the estimated risk was higher than 1:250. The best screening strategy with the lowest false-positive rate was obtained by combining the three serum markers. The results suggest that this kind of screening can be proposed during genetic counselling for women under 35 and older women wishing to avoid the risk of miscarriage induced by amniocentesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716761     DOI: 10.1002/pd.1970110406

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  4 in total

1.  Screening for Down's syndrome based on individual risk.

Authors:  M Lewis; M J Faed; P W Howie
Journal:  BMJ       Date:  1991-09-07

2.  First trimester prenatal diagnosis: earlier is not necessarily better.

Authors:  J A Boss
Journal:  J Med Ethics       Date:  1994-09       Impact factor: 2.903

Review 3.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

4.  Risk of fetal Down's syndrome based on maternal age and varying combinations of maternal serum markers.

Authors:  I Bartels; B Bockel; J Caesar; M Krawczak; M Thiele; R Rauskolb
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.